BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior.

Non-Melanoma skin cancer (NMSC) is the most commonly encountered malignancy in almost every area of practice, but the cases that present to an Otolaryngology practice will be advanced in nature.

The major subtypes of NMSC include basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, merkel cell carcinoma, and adnexal malignancies.

[MeSH-major] Carcinoma / pathology. Dermatofibrosarcoma / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology

[MeSH-minor] Humans. Neoplasm Metastasis. Organ Transplantation / adverse effects

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19239954.001).

[ISSN] 1532-818X

[Journal-full-title] American journal of otolaryngology

[ISO-abbreviation] Am J Otolaryngol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 123

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients.

BACKGROUND: The possibility of treating skin carcinomas of the pinna with radiotherapy is somewhat under discussion and scarcely known.

Therefore the aim of the study was to evaluate the effectiveness and safety of dermatologic radiotherapy in a series of patients affected by basal or squamous cell carcinoma of the pinna.

METHODS: A retrospective study was performed on 108 patients affected by 115 carcinomas of the pinna (99 basal cell carcinomas, 16 squamous cell carcinomas) without involvement of the external auditory canal.

During follow up a relapse was observed in 12 lesions (all basal cell carcinomas): nine central and three marginal to the irradiation field.

CONCLUSIONS: The results obtained confirm the possibility of treating epithelial skin neoplasms of the pinna with dermatologic radiotherapy, which can afford high-remission percentages without damaging cartilaginous tissue.

[MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Ear Neoplasms / radiotherapy. Ear, External. Skin Neoplasms / radiotherapy

[MeSH-minor] Aged. Aged, 80 and over. Esthetics. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Treatment Outcome

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15941445.001).

[ISSN] 0011-9059

[Journal-full-title] International journal of dermatology

[ISO-abbreviation] Int. J. Dermatol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immune protection, natural products, and skin cancer: is there anything new under the sun?

Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human neoplasms, representing one third of all new malignancies diagnosed in the US.

Ultraviolet (UV) radiation from the sun is a major cause of non-melanoma skin cancer in humans.

Aside from the mutagenic effects of UV radiation, there are suggestions from clinical studies and evidence in animal models that the immune system plays an important role in preventing skin cancer development and progression, and is suppressed by cutaneous exposure to UV radiation.

In this article, we review the research on new and existing agents that are being developed to protect the skin immune response from suppression by UV radiation.

[MeSH-major] Aloe. Antioxidants / therapeutic use. Carcinoma, Basal Cell. Phytotherapy. Skin Neoplasms. Ultraviolet Rays / adverse effects

MedlinePlus Health Information. consumer health - Antioxidants.

MedlinePlus Health Information. consumer health - Herbal Medicine.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. Sodium ascorbate .

Hazardous Substances Data Bank. L-Ascorbic Acid .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16774102.001).

[ISSN] 1545-9616

[Journal-full-title] Journal of drugs in dermatology : JDD

[ISO-abbreviation] J Drugs Dermatol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 1406-18-4 / Vitamin E; PQ6CK8PD0R / Ascorbic Acid

[Number-of-references] 67

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Mohs micrographic surgery is often considered the treatment of choice for a variety of skin malignancies.

In recent years, the application of immunostaining techniques has facilitated the successful removal of a number of common and less common cutaneous malignancies, including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, dermatofibrosarcoma protuberans, microcystic adnexal carcinoma, sebaceous carcinoma, atypical fibroxanthoma, extramammary Paget's disease, and even sarcomas.

Immunostains highlight the tumor cells and allow the Mohs surgeons to pinpoint and eliminate the residual tumor at the surgical margin.

It is especially helpful when a tumor presents with subtle or nonspecific histologic features or when a tumor is masked in a pocket of dense inflammation.

[MeSH-major] Mohs Surgery / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Staining and Labeling / methods

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19018832.001).

[ISSN] 1524-4725

[Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

[ISO-abbreviation] Dermatol Surg

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 127

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chemokine receptor expression in non-melanoma skin cancer.

Prior studies have shown that in metastatic melanoma and squamous cell carcinoma of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6.

However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma skin cancer have yet to be elucidated.

METHODS: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis, squamous cell carcinoma and basal cell carcinoma tissues.

RESULTS: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma skin cancer, invasive squamous cell carcinoma, but this pattern did not exist in non-melanoma skin cancer with no metastatic potential, basal cell carcinoma; or actinic keratosis, when compared with normal skin.

CONCLUSIONS: Chemokine receptor expression may influence the biological behavior of non-melanoma skin cancer.

[MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis / metabolism. Receptors, CCR6 / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism

[MeSH-minor] Analysis of Variance. Biomarkers / metabolism. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Metastasis / physiopathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Skin / metabolism. Skin / pathology. Staining and Labeling. Ultraviolet Rays / adverse effects. Up-Regulation

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18312436.001).

[ISSN] 1600-0560

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Biomarkers; 0 / CCR6 protein, human; 0 / CCR7 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR6; 0 / Receptors, CCR7; 0 / Receptors, CXCR4

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia.

Lectins represent one of pivotal regulators of the cell proliferation The potential of galectin-7 as a new prognostic marker was studied in normal and transformed squamous epithelia of both ectodermal (epidermis, cornea vs. trichoepithelioma, basal and squamous cell carcinoma) and endodermal (vocal fold epithelium vs. carcinoma) origin.

Its expression is significantly reduced in malignant cells, thus galectin-7 might be a differentiation marker of epithelial malignancies.

[MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epithelium / chemistry. Galectins / analysis

[MeSH-minor] Biomarkers, Tumor / analysis. Cell Division / physiology. Cells, Cultured. Humans. Tumor Cells, Cultured

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16315769.001).

[ISSN] 1214-6994

[Journal-full-title] Prague medical report

[ISO-abbreviation] Prague Med Rep

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Czech Republic

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectins; 0 / LGALS7 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: It is unclear if skin cancer risk is affected by the use of immunomodulatory medications in rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA).

METHODS: The English language literature on PubMed was searched with a combination of phrases, including "malignancy," "skin cancer," "squamous cell carcinoma," "basal cell carcinoma," "melanoma," "psoriasis," "psoriatic arthritis," and "rheumatoid arthritis" in addition to the generic names of a variety of common immunomodulatory drugs.

Treatment with tumor necrosis factor inhibitors increases the rates of non-melanoma skin cancer (NMSC) in RA and psoriasis.

Methotrexate may increase the risk of malignant melanoma in patients with RA and the risk of NMSC in psoriasis.

More careful recording of skin cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.

[MeSH-major] Arthritis, Psoriatic / therapy. Arthritis, Rheumatoid / therapy. Immunosuppression / adverse effects. Psoriasis / therapy. Skin Neoplasms / etiology

Genetic Alliance. consumer health - Arthritis.

Genetic Alliance. consumer health - Psoriasis.

Genetic Alliance. consumer health - Psoriatic Arthritis.

Genetic Alliance. consumer health - Rheumatoid arthritis.

MedlinePlus Health Information. consumer health - Psoriasis.

MedlinePlus Health Information. consumer health - Psoriatic Arthritis.

MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20810498.001).

[ISSN] 0315-162X

[Journal-full-title] The Journal of rheumatology

[ISO-abbreviation] J. Rheumatol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Canada

[Chemical-registry-number] 0 / Immunologic Factors

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.

Patched1 heterozygous mice (Ptch1(+/-)) are useful for basal cell carcinoma (BCC) studies, being remarkably susceptible to BCC induction by ultraviolet or ionizing radiation.

Analogously, skin carcinogenesis-susceptible (Car-S) mice are elective for studies of papilloma and squamous cell carcinoma (SCC) induction.

We previously reported a striking effect of gender on BCC induction in Ptch1(+/-) mice, with total resistance of females; likewise, Car-S females show increased skin tumor resistance relative to males.

Here, we investigated the protective role of endogenous estrogen in skin keratinocyte tumorigenesis.

Control (CN) and ovariectomized Ptch1(+/-) or Car-S females were irradiated for BCC induction or topically treated with chemical carcinogens for SCC induction.

Susceptibility to BCC or SCC was dramatically increased in ovariectomized Ptch1(+/-) and Car-S females and restored to levels observed in males.

Remarkably, progression of initially benign papillomas to malignant SCC occurred only in ovariectomized Car-S females.

We explored the mechanisms underlying tumor progression and report overexpression of estrogen receptor (ER)-alpha, downregulation of ERbeta and upregulation of cyclin D1 in papillomas from ovariectomized Car-S relative to papillomas from CN females.

Thus, an imbalanced ERalpha/ERbeta expression may be associated with estrogen-mediated modulation of non-melanoma skin carcinogenesis, with a key role played by cyclin D1.

Our findings underscore a highly protective role of endogenous estrogen against skin tumorigenesis by diverse agents in two independent mouse models of skin cancer.

[MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Estrogens / physiology. Skin Neoplasms / metabolism

[MeSH-minor] Animals. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Cyclin D1 / metabolism. Disease Models, Animal. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Male. Mice. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Ovariectomy. Papilloma / metabolism. Papilloma / pathology. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Ultraviolet Rays

MedlinePlus Health Information. consumer health - Skin Cancer.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Carcinogenesis. 2009 Apr;30(4):720 [19168587.001]

(PMID = 18952596.001).

[ISSN] 1460-2180

[Journal-full-title] Carcinogenesis

[ISO-abbreviation] Carcinogenesis

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Receptors, Cell Surface; 0 / patched receptors; 136601-57-5 / Cyclin D1

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.

Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.

These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.

Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.

Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.

As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.

Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.

[MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology

[MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

MedlinePlus Health Information. consumer health - Skin Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16258517.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A

[Number-of-references] 71

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basosquamous carcinoma: treatment with Mohs micrographic surgery.

BACKGROUND: Basosquamous carcinoma (BSC) is a rare tumor defined as a basal cell carcinoma (BCC) differentiating into squamous cell carcinoma (SCC).

METHODS: The prospective, multicenter case series included all patients in Australia treated with MMS for BSC, who were monitored by the Skin and Cancer Foundation Australia between 1993 and 2002.

The tumors were diagnosed initially as BCC in 87.4% and as SCC in 12.0% of patients.

Of 98 patients who completed a 5-year follow-up period after MMS, 4 (4.1%) had disease recurrence.

CONCLUSIONS: The low 5-year disease recurrence rate of BSC with MMS emphasized the importance of margin-controlled excision using MMS.

[MeSH-major] Carcinoma, Basosquamous / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods

[MeSH-minor] Adult. Aged. Arm. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged. Neoplasm Recurrence, Local

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15929123.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Multicenter Study

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Specific penoscrotal neoplasias discussed in this article include invasive and in situ squamous cell carcinoma, basal cell carcinoma, extramammary Paget disease, and granular cell tumor.

[MeSH-minor] Carcinoma, Squamous Cell / surgery. Humans. Male. Paget Disease, Extramammary / surgery. Penile Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Inc. All rights reserved.

(PMID = 20674695.001).

[ISSN] 1558-318X

[Journal-full-title] The Urologic clinics of North America

[ISO-abbreviation] Urol. Clin. North Am.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose.

Basal cell carcinoma (BCC) is an indolent, slow-growing malignant skin tumour.

The nose is a common site for malignant skin tumours, such as basal cell carcinoma and squamous cell carcinoma because it is exposed to the sun.

Excision of the BCC will leave the nose with a soft tissue defect which requires reconstruction.

This report illustrates a case of BCC of nose whereby a wide excision and reconstruction was performed with a paramedian forehead flap.

[MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Surgical Flaps

MedlinePlus Health Information. consumer health - Nasal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19385500.001).

[ISSN] 0300-5283

[Journal-full-title] The Medical journal of Malaysia

[ISO-abbreviation] Med. J. Malaysia

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Malaysia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.

OBJECTIVE: To identify predictors of skin-related quality of life (QOL) after treatment of nonmelanoma skin cancer (NMSC).

SETTING: University-affiliated private practice and a Veterans Affairs clinic.

MAIN OUTCOME MEASURE: Skin-related QOL, measured with the 16-item version of Skindex-16, a validated measure.

RESULTS: Controlling for treatment group, the strongest independent predictor of skin-related QOL after treatment of NMSC was pretreatment skin-related QOL.

No tumor or care characteristic (including location of tumor, size of tumor, site of therapy, or training level of treating clinician [attending physician, resident, or nurse practitioner]) was found to predict better skin-related QOL after treatment of NMSC.

CONCLUSIONS: Patients with better pretreatment skin-related QOL, less comorbidity, and better mental health status had better skin-related QOL after treatment of NMSC.

[MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Quality of Life. Skin / physiopathology. Skin Neoplasms / therapy

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Arch Dermatol. 2007 Nov;143(11):1429-32 [18025368.001]

[ErratumIn] Arch Dermatol. 2008 Feb;144(2):230

(PMID = 18025362.001).

[ISSN] 1538-3652

[Journal-full-title] Archives of dermatology

[ISO-abbreviation] Arch Dermatol

[Language] eng

[Grant] United States / NIAMS NIH HHS / AR / K02 AR02203; United States / NIAMS NIH HHS / AR / K24-AR052667

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Skin cancer of the head and neck.

The majority of skin cancers of the head and neck are nonmelanoma skin cancers (NMSC).

Basal cell carcinoma and squamous cell carcinoma are the most frequent types of NMSC.

Malignant melanoma is an aggressive neoplasm of skin, and the ideal adjuvant therapy has not yet been found, although various options for treatment of skin cancer are available to the patient and physician, allowing high cure rate and excellent functional and cosmetic outcomes.

Sunscreen protection and early evaluation of suspicious areas remain the first line of defense against skin cancers.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 22550432.001).

[ISSN] 1535-2188

[Journal-full-title] Seminars in plastic surgery

[ISO-abbreviation] Semin Plast Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3324239

[Keywords] NOTNLM ; Basal cell carcinoma / Mohs' micrographic surgery / melanoma / nonmelanoma skin cancer / squamous cell carcinoma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Currently, topical photodynamic therapy (PDT) has received approval for the treatment of dermato-oncologic conditions like actinic keratoses, Bowen's disease, in-situ squamous cell carcinoma and basal cell carcinoma in many countries all over the world.

Due to the easy accessibility of skin to light activation, incoherent lamps or LED arrays are suitable for PDT.

Either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving inflammatory skin conditions are induced.

Treating superficial non-melanoma skin cancer, PDT has been shown to be highly efficient despite the low level of invasiveness.

[MeSH-major] Photochemotherapy. Skin Diseases / drug therapy. Skin Neoplasms / drug therapy

[MeSH-minor] Carcinoma, Basal Cell / drug therapy. Humans

MedlinePlus Health Information. consumer health - Skin Cancer.

MedlinePlus Health Information. consumer health - Skin Conditions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16935788.001).

[ISSN] 1167-1122

[Journal-full-title] European journal of dermatology : EJD

[ISO-abbreviation] Eur J Dermatol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] France

[Number-of-references] 80

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Changes in life style over the past several decades including much of the time spent outdoors and the use of tanning devices for cosmetic purposes by individuals have led to an increase in the incidence of solar ultraviolet (UV) radiation-induced skin diseases including the risk of skin cancers.

Solar UV radiations are considered as the most prevalent environmental carcinogens, and chronic exposure of the skin to UV leads to squamous and basal cell carcinoma and melanoma in human population.

Silymarin is one of them and extensively studied for its skin photoprotective capabilities.

), and has been shown to have chemopreventive effects against photocarcinogenesis in mouse tumor models.

Topical treatment of silymarin inhibited photocarcinogenesis in mice in terms of tumor incidence, tumor multiplicity and growth of the tumors.

It is suggested that silymarin may favorably supplement sunscreen protection, and may be useful for skin diseases associated with solar UV radiation-induced inflammation, oxidative stress and immunomodulatory effects.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Science. 1993 Apr 23;260(5107):496-7 [8097337.001]

[Cites] Science. 1993 Apr 23;260(5107):547-9 [8097338.001]

[Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):846-8 [8388060.001]

[Cites] Immunol Today. 1993 Jul;14(7):335-8 [8103338.001]

[Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]

[Cites] Photochem Photobiol. 1993 Dec;58(6):813-7 [8310001.001]

[Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]

[Cites] Carcinogenesis. 1994 Jun;15(6):1099-103 [8020140.001]

[Cites] J Invest Dermatol. 1994 Aug;103(2):211-6 [8040612.001]

[Cites] J Leukoc Biol. 1994 Dec;56(6):769-75 [7996051.001]

[Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]

[Cites] J Immunol. 1995 May 15;154(10):5114-20 [7730617.001]

[Cites] J Immunol. 1995 Nov 15;155(10):4661-8 [7594465.001]

[Cites] Photochem Photobiol. 1995 Nov;62(5):855-61 [8570723.001]

[Cites] J Cell Biol. 1996 Apr;133(1):211-20 [8601609.001]

[Cites] J Biol Chem. 1996 Apr 5;271(14):8285-94 [8626523.001]

[Cites] Cancer Res. 1996 Mar 1;56(5):1023-30 [8640756.001]

[Cites] J Invest Dermatol. 1996 Jun;106(6):1187-91 [8752655.001]

[Cites] Photochem Photobiol. 1996 Apr;63(4):356-7 [8934734.001]

[Cites] Photochem Photobiol. 1996 Apr;63(4):380-3 [8934743.001]

[Cites] J Immunol. 1996 Dec 15;157(12):5254-61 [8955170.001]

[Cites] J Natl Cancer Inst. 1997 Apr 16;89(8):556-66 [9106644.001]

[Cites] Int J Oncol. 2002 Dec;21(6):1213-22 [12429970.001]

[Cites] Carcinogenesis. 2003 May;24(5):927-36 [12771038.001]

[Cites] Carcinogenesis. 2003 Aug;24(8):1379-88 [12807737.001]

[Cites] J Invest Dermatol. 2003 Oct;121(4):862-8 [14632206.001]

[Cites] J Invest Dermatol. 2004 Feb;122(2):510-7 [15009738.001]

[Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):681-6 [9591810.001]

[Cites] J Cell Biochem Suppl. 1997;27:59-67 [9591194.001]

[Cites] J Invest Dermatol. 1998 Jun;110(6):966-71 [9620307.001]

[Cites] Br J Dermatol. 1998 Jul;139(1):3-10 [9764141.001]

[Cites] J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):611-25 [9777769.001]

[Cites] Cancer Res. 1999 Feb 1;59(3):622-32 [9973210.001]

[Cites] Nat Med. 1999 Apr;5(4):418-22 [10202931.001]

[Cites] Br J Dermatol. 1999 Feb;140(2):255-8 [10233218.001]

[Cites] J Invest Dermatol. 1999 May;112(5):751-6 [10233767.001]

[Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 1):697-701 [10321596.001]

[Cites] Am J Health Syst Pharm. 1999 Jun 15;56(12):1195-7 [10484652.001]

[Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]

[Cites] Carcinogenesis. 2005 Aug;26(8):1404-13 [15831527.001]

[Cites] Mol Cancer Ther. 2006 Jul;5(7):1660-8 [16891451.001]

[Cites] J Dermatol Sci. 2007 Apr;46(1):21-30 [17289350.001]

[Cites] J Dermatol Sci. 2007 Dec;48(3):213-24 [17689055.001]

[Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):266-71 [18221354.001]

[Cites] J Invest Dermatol. 2009 May;129(5):1258-70 [19020550.001]

[Cites] Cancer Prev Res (Phila). 2010 Feb;3(2):179-89 [20103727.001]

[Cites] J Exp Med. 1998 Apr 6;187(7):1133-8 [9529329.001]

[Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):97-100 [10537017.001]

[Cites] Carcinogenesis. 1999 Nov;20(11):2117-24 [10545414.001]

[Cites] Cancer Lett. 1999 Dec 1;147(1-2):77-84 [10660092.001]

[Cites] Int Urol Nephrol. 1999;31(4):417-22 [10668934.001]

[Cites] J Heart Lung Transplant. 2000 Mar;19(3):249-55 [10713249.001]

[Cites] Liver Transpl. 2000 May;6(3):253-62 [10827224.001]

[Cites] Carcinogenesis. 2001 Feb;22(2):287-94 [11181450.001]

[Cites] Int J Oncol. 2001 Jun;18(6):1307-13 [11351267.001]

[Cites] J Leukoc Biol. 2001 May;69(5):719-26 [11358979.001]

[Cites] Photochem Photobiol. 2001 Jun;73(6):600-4 [11421064.001]

[Cites] Photochem Photobiol. 2001 Jun;73(6):621-9 [11421067.001]

[Cites] J Invest Dermatol. 2001 Jul;117(1):147-50 [11442762.001]

[Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):110-7 [11601887.001]

[Cites] Drugs. 2001;61(14):2035-63 [11735632.001]

[Cites] Photochem Photobiol. 2001 Dec;74(6):787-93 [11783934.001]

[Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]

[Cites] Carcinogenesis. 2002 Mar;23(3):499-510 [11895866.001]

[Cites] Sci STKE. 2003 Jan 28;2003(167):RE2 [12554854.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):6349-56 [15342425.001]

[Cites] Arzneimittelforschung. 1968 Jun;18(6):688-96 [5755805.001]

[Cites] Arzneimittelforschung. 1974 Apr;24(4):466-71 [4408125.001]

[Cites] J Natl Cancer Inst. 1974 Nov;53(5):1333-6 [4139281.001]

[Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5574-8 [271984.001]

[Cites] Br J Clin Pharmacol. 1978 May;5(5):431-6 [656282.001]

[Cites] J Immunol. 1980 Jan;124(1):445-53 [6153101.001]

[Cites] Br Med J. 1979 Dec 8;2(6203):1461-6 [393355.001]

[Cites] Scand J Gastroenterol. 1982 Jun;17(4):517-21 [6753109.001]

[Cites] Science. 1983 Sep 23;221(4617):1256-64 [6351251.001]

[Cites] Immunol Rev. 1984 Aug;80:87-102 [6237978.001]

[Cites] Cancer Res. 1986 May;46(5):2203-7 [3516380.001]

[Cites] J Hepatol. 1989 Jul;9(1):105-13 [2671116.001]

[Cites] J Exp Med. 1989 Oct 1;170(4):1117-31 [2529340.001]

[Cites] Semin Dermatol. 1990 Mar;9(1):25-31 [2203440.001]

[Cites] J Invest Dermatol. 1990 Oct;95(4):436-40 [2120354.001]

[Cites] J Invest Dermatol. 1990 Nov;95(5):530-6 [2230216.001]

[Cites] Pharm Res. 1991 Feb;8(2):273-7 [1902564.001]

[Cites] Dermatol Clin. 1991 Oct;9(4):751-5 [1934649.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7516-20 [1502162.001]

[Cites] J Exp Med. 1993 Apr 1;177(4):1199-204 [8096238.001]

(PMID = 20372777.001).

[ISSN] 1791-2423

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R03 CA105368-01; United States / NCI NIH HHS / CA / R03 CA105368; United States / NCI NIH HHS / CA / R03 CA105368-02; United States / NCI NIH HHS / CA / CA105368-02; United States / NCI NIH HHS / CA / CA105368-01; United States / NCI NIH HHS / CA / CA105368

[Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review

[Publication-country] Greece

[Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Plant Extracts; 0 / Silymarin

[Other-IDs] NLM/ NIHMS184206; NLM/ PMC2852174

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.

BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.

MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence, disease-free follow-up, and adverse events.

When managing superficial skin tumors with PNI, a multidisciplinary team including a cutaneous surgeon and a radiation oncologist familiar with PNI is recommended.

[MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy

[MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Bell's Palsy.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19018830.001).

[ISSN] 1524-4725

[Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

[ISO-abbreviation] Dermatol Surg

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas.

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive tumour for which an increasing incidence has been reported.

A new human polyomavirus, Merkel cell polyomavirus (MCV), was recently isolated from these tumours by applying digital transcriptome subtraction methodology.

METHODS: Nine primary or recurrent MCCs from seven patients were examined; 29 other tumours (squamous cell, basal cell and basosquamous carcinomas and malignant melanomas) were examined for comparative purposes.

[MeSH-major] Antigens, Viral, Tumor / genetics. Capsid Proteins / genetics. Carcinoma, Merkel Cell / virology. Polyomaviridae / genetics. Polyomavirus Infections / virology. Skin Neoplasms / virology

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19438857.001).

[ISSN] 1365-2133

[Journal-full-title] The British journal of dermatology

[ISO-abbreviation] Br. J. Dermatol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Capsid Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines].

[Transliterated title] Stellenwert der Zellkulturmodelle in kutaner Tumorbiologie. Teil I: Zelllinien tumorigen transformierter Zellen.

Cutaneous squamous cell carcinoma, basal cell carcinoma and melanoma, much like all other human solid tumors, result from a multi-step process in which genetic and epigenetic changes accumulate in the affected cells.

Cell culture models are a very valuable experimental system.

Tumor cell lines display similar functional hierarchy as tumors or tissues in vivo and can, consequently, provide a crucial source of minor cell subsets, like tumor stem cells.

Progression series of clonally related cell lines offer the opportunity to follow the process of sequential acquisition of transformation-related traits up to the development of properties with direct clinical equivalents, like tumorigenicity and metastatic competence.

While for most studies, human transformed cell lines are the model of choice, there are questions for which animal cell lines are strongly preferred, such as interactions between the tumor and the immune system.

To properly interpret the results of all experiments with classical two-dimensional cell culture, a possible danger of artifacts due to grossly unnatural environment must be constantly taken into account.

[MeSH-major] Cell Line, Tumor / pathology. Cell Line, Tumor / physiology. Disease Models, Animal. Skin Neoplasms / pathology. Skin Neoplasms / physiopathology

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oncogene. 2004 Jan 8;23(1):30-8 [14712208.001]

[Cites] Annu Rev Pathol. 2007;2:175-89 [18039097.001]

[Cites] Am J Pathol. 1999 Aug;155(2):441-52 [10433937.001]

[Cites] Am J Pathol. 2000 Jan;156(1):159-67 [10623663.001]

[Cites] Ann N Y Acad Sci. 2003 May;995:151-61 [12814947.001]

[Cites] Cancer Genet Cytogenet. 2003 Apr 15;142(2):87-91 [12699882.001]

[Cites] Cancer Res. 2003 Nov 1;63(21):7147-57 [14612508.001]

[Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]

[Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4359-70 [9494534.001]

[Cites] Mol Carcinog. 1998 Nov;23(3):144-58 [9833775.001]

[Cites] J Surg Res. 1995 Feb;58(2):165-74 [7861768.001]

[Cites] Cancer Res. 1996 Jul 1;56(13):3075-86 [8674065.001]

[Cites] Cancer Res. 1990 Apr 15;50(8):2296-302 [2156614.001]

[Cites] J Cell Biochem. 1994 Feb;54(2):161-73 [8175891.001]

[Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]

[Cites] Exp Dermatol. 2007 Apr;16(4):297-301 [17359335.001]

[Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):365-78 [14973382.001]

[Cites] Exp Dermatol. 2000 Apr;9(2):104-17 [10772384.001]

[Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]

[Cites] Annu Rev Cell Dev Biol. 2006;22:339-73 [16824012.001]

[Cites] Arch Dermatol. 1996 Oct;132(10):1185-93 [8859029.001]

[Cites] J Invest Dermatol. 2006 Jun;126(6):1372-7 [16470173.001]

[Cites] Cancer Res. 2005 May 15;65(10 ):4320-33 [15899824.001]

[Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]

[Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]

[Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5670-6 [4053039.001]

[Cites] J Invest Dermatol. 2005 Feb;124(2):401-4 [15675960.001]

[Cites] Exp Cell Res. 2000 Aug 1;258(2):352-60 [10896786.001]

[Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]

[Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]

[Cites] Cancer Res. 1991 Apr 15;51(8):2205-11 [2009539.001]

[Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]

[Cites] Cancer Res. 1996 Feb 15;56(4):875-9 [8631027.001]

[Cites] Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32 [17654417.001]

[Cites] J Invest Dermatol. 2006 Jun;126(6):1214-6 [16702970.001]

[Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]

[Cites] Cancer Res. 1980 May;40(5):1636-44 [7370995.001]

[Cites] Histol Histopathol. 2002;17 (3):951-9 [12168807.001]

[Cites] J Invest Dermatol. 2000 Dec;115(6):1095-103 [11121147.001]

[Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]

[Cites] Blood. 2003 Nov 15;102(10):3837-44 [12881305.001]

[Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]

[Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]

[Cites] J Invest Dermatol. 2005 Feb;124(2):457-65 [15675968.001]

[Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]

[Cites] Prostate. 1986;9(3):261-81 [3774632.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]

[Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]

[Cites] Schweiz Med Wochenschr. 2000 Apr 29;130(17):617-24 [10829299.001]

[Cites] Hautarzt. 2004 Oct;55(10):942-51 [15349693.001]

[Cites] Pathologe. 1994 Jun;15(3):141-9 [8072948.001]

[Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]

[Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]

[Cites] World J Gastroenterol. 2002 Dec;8(6):976-81 [12439909.001]

[Cites] Int J Cancer. 1995 Mar 3;60(5):668-75 [7532159.001]

[Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]

[Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]

(PMID = 18058078.001).

[ISSN] 1432-1173

[Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete

[ISO-abbreviation] Hautarzt

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Germany

[Number-of-references] 64

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.

OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC.

STUDY SELECTION: Prospective, retrospective, and case studies in English containing a minimum of 4 subjects and a 6-month follow-up or posttreatment histologic evaluation.

DATA EXTRACTION: We calculated the rate of clearance and adverse effects for BCC subtypes and invasive and in situ SCC treated with topical imiquimod or fluorouracil.

Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC, 42% to 100% for nodular BCC, 56% to 63% for infiltrative BCC, 73% to 88% for SCC in situ, and 71% for invasive SCC.

Fluorouracil use produced the following clearance rates: 90% for superficial BCC and 27% to 85% for SCC in situ.

CONCLUSIONS: Evidence supports the use of topical imiquimod as monotherapy for superficial BCC and topical fluorouracil as monotherapy for superficial BCC and SCC in situ.

[MeSH-major] Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / pharmacokinetics. Skin Neoplasms / drug therapy

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. Imiquimod .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

PubMed Health. DARE review .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20026854.001).

[ISSN] 1538-3652

[Journal-full-title] Archives of dermatology

[ISO-abbreviation] Arch Dermatol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil

[Number-of-references] 47

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Reasons for the increased incidence of skin cancer].

The cutaneous malignancies with an increasing incidence in Japan are squamous cell carcinoma, basal cell carcinoma, and malignant melanoma.

According to a nationwide questionnaire survey (responses from 94 centers), basal cell carcinoma has the highest incidence and accounts for nearly 50% of all skin malignancies, followed by squamous cell carcinoma (31%) and malignant melanoma (21%).

The number of cases of each tumor has grown annually, and comparison of the percent increases between 1987 and 2001 shows an increase of about 1.5-fold for basal cell carcinoma or 1.7-fold for squamous cell carcinoma or malignant melanoma.

Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, the Malignant Skin Tumor Research Group has been investigating the factors behind these increases by detailed statistical analysis of data obtained from 1987 onwards from designated centers (19-22 centers).

[MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17033224.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Photosensitizing medication use and risk of skin cancer.

Whether use of these medications affects skin cancer risk, however, is unclear.

METHODS: Using a cohort of all Danish residents ≥15 years old in 1995 to 2006 (n = 4,761,749) and information from Danish national registers, we examined associations between use of photosensitizing medications and risk of basal cell carcinoma, cutaneous malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma.

RESULTS: Users of only 2 of 19 medications for long-term use (methyldopa and furosemide) had both a ≥20% increased risk of skin cancer (compared with nonusers) and an increase in risk with increasing duration of use; these effects were limited to basal cell carcinoma and squamous cell carcinoma, respectively.

In contrast, 8 of 10 medications for short-term use were associated with both a ≥20% increased risk of skin cancer and an increase in risk with increasing use for at least one of the four cancers.

CONCLUSION: We found little evidence of an increased risk of skin cancer among users of photosensitizing medications for long-term daily use, but could not rule out the possibility that users of some photosensitizing medications for short-term use may have an increased risk of skin cancer.

Our study examined the effect of a wide range of photosensitizing medications on skin cancer risk and suggests that future work should focus on photosensitizing medications for short-term use.

[MeSH-major] Photosensitivity Disorders / chemically induced. Prescription Drugs / adverse effects. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] ©2010 AACR.

(PMID = 20861398.001).

[ISSN] 1538-7755

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Prescription Drugs

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multimodal confocal microscopy for diagnosing nonmelanoma skin cancers.

BACKGROUND AND SIGNIFICANCE: The standard diagnostic procedure for skin cancers is invasive biopsy followed by histopathological evaluation.

In this study, the suitability of dye-enhanced multimodal confocal microscopy for the detection of nonmelanoma skin cancers was evaluated.

MATERIALS AND METHODS: For the experiments we used fresh tumor material stained using 0.2 mg/ml or 0.05 mg/ml aqueous solutions of methylene blue (MB) or toluidine blue (TB), respectively.

Reflectance, fluorescence, and fluorescence polarization images of skin specimens stained with MB and TB were excited by 656 nm and 633 nm light, respectively.

In total we imaged, analyzed, and compared to histology at least 10 samples of each tumor-type including nodular basal cell carcinoma (BCC), infiltrative basal cell carcinoma, and squamous cell carcinoma (SCC).

RESULTS AND CONCLUSION: The morphological features and appearance of skin structures in the fluorescence images correlate well with corresponding histology for all investigated tumor-types.

Our results indicate the feasibility of using multimodal confocal microscopy as real-time tool for detecting skin pathology.

[MeSH-major] Microscopy, Confocal. Skin Neoplasms / pathology

[MeSH-minor] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Coloring Agents. Diagnosis, Differential. Equipment Design. Humans. In Vitro Techniques. Methylene Blue. Staining and Labeling. Tolonium Chloride

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. METHYLENE BLUE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2007 Wiley-Liss, Inc

(PMID = 17960751.001).

[ISSN] 0196-8092

[Journal-full-title] Lasers in surgery and medicine

[ISO-abbreviation] Lasers Surg Med

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride; T42P99266K / Methylene Blue

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation.

CONTEXT: In the SU.VI.MAX study, antioxidant supplementation for 7.5 years was found to increase skin cancer risk in women but not in men.

OBJECTIVE: To investigate the potential residual or delayed effect of antioxidant supplementation on skin cancer incidence after a 5-year post-intervention follow-up.

DESIGN, SETTING AND PARTICIPANTS: Assessment of skin cancer including melanoma and non-melanoma during the post-intervention follow-up (September 2002-August 2007).

MAIN OUTCOME MEASURES: Total skin cancer incidence, including melanoma, squamous cell carcinoma and basal cell carcinoma.

Six squamous cell carcinomas were found in women and 15 in men (10 and 25, respectively, for the total period).

Finally, 40 basal cell carcinomas appeared in women and 36 in men (98 and 94, respectively, for the total period).

No delayed effects, either on melanoma or non-melanoma skin cancers, were observed for either gender.

CONCLUSIONS: The risk of skin cancers associated with antioxidant intake declines following interruption of supplementation.

This supports a causative role for antioxidants in the evolution of skin cancers.

[MeSH-major] Antioxidants / adverse effects. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Vitamins / adverse effects

MedlinePlus Health Information. consumer health - Antioxidants.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.

(PMID = 20605091.001).

[ISSN] 1879-0852

[Journal-full-title] European journal of cancer (Oxford, England : 1990)

[ISO-abbreviation] Eur. J. Cancer

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00272428

[Publication-type] Journal Article; Randomized Controlled Trial

[Publication-country] England

[Chemical-registry-number] 0 / Antioxidants; 0 / Vitamins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Atypical cellular neurothekeoma is a rare neoplasm generally regarded as a benign tumor with locally aggressive behavior.

Recurrence is common with inadequate excision, but metastatic disease has yet to be reported.

RESULTS: The neoplasm was extirpated in a three-stage, five section Mohs surgery procedure.

CONCLUSION: Mohs micrographic surgery is unsurpassed in its efficacy in treating a wide variety of nonmelanoma skin cancers.

Although most commonly used to address basal and squamous cell carcinoma, it has also been reported as a successful treatment for melanoma and a wide variety of cutaneous malignancies.

Debate in the literature is ongoing regarding the true histogenesis of this rare tumor.

Because of this tumor's local destructive behavior and propensity to recur with inadequate resection, we recommend Moths micrographic surgery for the treatment of cellular neurothekeomas.

MedlinePlus Health Information. consumer health - Nasal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Dermatol Surg. 2008 Mar;34(3):428 [18248473.001]

(PMID = 16681671.001).

[ISSN] 1076-0512

[Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

[ISO-abbreviation] Dermatol Surg

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 21

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The effect of c-myc on stem cell fate influences skin tumor phenotype.

Nonmelanoma skin cancers (NMSCs) consist of a variety of tumor types including basal cell carcinoma, squamous cell carcinoma, a variety of hair follicle tumors, and sebaceous gland tumors.

Our goal in the current study was to determine if alterations in the commitment of multipotent stem cells to different cell fates would influence tumor phenotype.

[MeSH-major] Proto-Oncogene Proteins c-myc / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology. Stem Cells / pathology

[MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma, Sebaceous / pathology. Animals. Carcinogens / toxicity. Cell Differentiation / genetics. Cell Lineage / genetics. Crosses, Genetic. Female. Heterozygote. Male. Mice. Mice, Inbred ICR. Mice, Inbred Strains. Mice, Transgenic. Multipotent Stem Cells / pathology. Papilloma / pathology. Phenotype. Sebaceous Gland Neoplasms / pathology. Tetradecanoylphorbol Acetate / pharmacology. Transgenes

MedlinePlus Health Information. consumer health - Skin Cancer.

MedlinePlus Health Information. consumer health - Stem Cells.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20146250.001).

[ISSN] 1098-2744

[Journal-full-title] Molecular carcinogenesis

[ISO-abbreviation] Mol. Carcinog.

[Language] eng

[Grant] United States / NIAMS NIH HHS / AR / AR47898; United States / NCI NIH HHS / CA / CA09197; United States / NCI NIH HHS / CA / CA105491; United States / NCI NIH HHS / CA / CA52607; United States / NCI NIH HHS / CA / CA79998

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Carcinogens; 0 / Proto-Oncogene Proteins c-myc; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

They are then able to check other sun-exposed areas such as the face, ears, scalp, back and limbs to discover any other lesions or more serious problems of basal cell carcinoma, squamous cell carcinoma or malignant melanoma the would require referral, sometimes urgently, to a dermatologist for full assessment and treatment.

[MeSH-major] Keratosis / nursing. Skin Neoplasms / nursing. Sunlight / adverse effects

[MeSH-minor] Community Health Nursing. Diagnosis, Differential. Humans. Nursing Diagnosis. Protective Clothing. Risk Factors. Sunscreening Agents

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20216512.001).

[ISSN] 1462-4753

[Journal-full-title] British journal of community nursing

[ISO-abbreviation] Br J Community Nurs

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Sunscreening Agents

[Number-of-references] 13

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment options for non-melanoma skin cancer.

Non melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) are becoming more common.

[MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Skin Neoplasms / therapy

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19755949.001).

[ISSN] 0392-0488

[Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia

[ISO-abbreviation] G Ital Dermatol Venereol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Italy

[Number-of-references] 38

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen's disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma.

In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma.

To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated squamous cell carcinoma of the eyelid.

[MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Eyelid Neoplasms / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy

[MeSH-minor] Administration, Topical. Aged. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Ophthalmic Solutions. Retrospective Studies. Treatment Outcome

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. Imiquimod .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20394545.001).

[ISSN] 1744-5108

[Journal-full-title] Orbit (Amsterdam, Netherlands)

[ISO-abbreviation] Orbit

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ophthalmic Solutions; 99011-02-6 / imiquimod

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Patients infected with human immunodeficiency virus (HIV) have an increased risk of developing skin cancers.

This article will review and discuss management issues for the following malignancies: lymphomas, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and Kaposi's sarcoma.

[MeSH-major] HIV Infections / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

[MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / complications. Melanoma / diagnosis. Melanoma / therapy. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / therapy

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15842615.001).

[ISSN] 1396-0296

[Journal-full-title] Dermatologic therapy

[ISO-abbreviation] Dermatol Ther

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Denmark

[Number-of-references] 148

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma.

[MeSH-major] Antigens, CD56 / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18798745.001).

[ISSN] 1524-4725

[Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

[ISO-abbreviation] Dermatol Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD56

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The DeltaN-p63 isoforms of p63, which are believed to behave as oncogenes, are expressed in squamous cell carcinoma, basal cell carcinoma, and transitional cell carcinoma.

We studied 66 cases of thymoma (1 type A, 8 type AB, 12 type B1, 19 type B2, 12 type B3, and 14 type C/thymic carcinoma) and 10 specimens of normal human thymus arranged in tissue microarrays.

All thymomas (including thymic carcinomas) were positive for p63 regardless of type.

[MeSH-major] DNA-Binding Proteins / biosynthesis. Thymoma / metabolism. Thymus Gland / chemistry. Thymus Neoplasms / metabolism. Trans-Activators / biosynthesis. Tumor Suppressor Proteins / biosynthesis

MedlinePlus Health Information. consumer health - Thymus Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17276940.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Photodynamic therapy for non-melanoma skin cancer.

Photodynamic therapy is a treatment modality that has been shown to be effective mainly for the dermato-oncologic conditions: actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and basal cell carcinoma.

For actinic keratosis and basal cell carcinoma, methyl aminolevulinate-photodynamic therapy is already approved in Europe, Australia and New Zealand, and is now also approved for actinic keratosis in the US.

[MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy

[MeSH-minor] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Humans. Photosensitizing Agents

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16396794.001).

[ISSN] 0001-5555

[Journal-full-title] Acta dermato-venereologica

[ISO-abbreviation] Acta Derm. Venereol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Norway

[Chemical-registry-number] 0 / Photosensitizing Agents

[Number-of-references] 51

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Only one patient had the diagnosis of chronic leukemia, others had no preexisting history of systemic disease.

Three patients had abnormal pathology: Lymphoproliferative disease in the patient with chronic leukemia, granulomatous inflammation, and basosquamous cell carcinoma.

Even though rare, malignant or systemic disease in patients with neither specific history nor clinical or radiological finding might be observed in these cases.

Thus, we recommend taking biopsy if any suspicion of abnormality of the lacrimal sac exists.

[MeSH-major] Lacrimal Duct Obstruction / diagnosis. Nasolacrimal Duct / pathology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Dacryocystorhinostomy. Female. Humans. Lacrimal Apparatus Diseases / diagnosis. Male. Middle Aged. Prospective Studies. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20704489.001).

[ISSN] 1744-5108

[Journal-full-title] Orbit (Amsterdam, Netherlands)

[ISO-abbreviation] Orbit

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nutrition and nonmelanoma skin cancers.

The incidence of nonmelanoma skin cancer is increasing every year.

Basal cell carcinoma and squamous cell carcinoma are the two major types of nonmelanoma skin cancer.

Among other factors, understanding the potential role of nutrients in the development, progression, and treatment of nonmelanoma skin cancer is critical.

This contribution provides a review of the nutrients that have been more extensively investigated in the literature with regard to nonmelanoma skin cancer, including dietary fats, retinol, carotenoids, vitamin C, vitamin D, vitamin E, selenium, copper, iron, zinc, green tea, and black tea.

[MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Diet. Micronutrients / administration & dosage. Skin Neoplasms

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. Green tea .

Hazardous Substances Data Bank. Sodium ascorbate .

Hazardous Substances Data Bank. L-Ascorbic Acid .

Hazardous Substances Data Bank. VITAMIN A .

Hazardous Substances Data Bank. IRON, ELEMENTAL .

Hazardous Substances Data Bank. COPPER, ELEMENTAL .

Hazardous Substances Data Bank. ZINC, ELEMENTAL .

Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.

(PMID = 21034989.001).

[ISSN] 1879-1131

[Journal-full-title] Clinics in dermatology

[ISO-abbreviation] Clin. Dermatol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Dietary Fats; 0 / Micronutrients; 0 / Tea; 11103-57-4 / Vitamin A; 1406-16-2 / Vitamin D; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; 789U1901C5 / Copper; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc; PQ6CK8PD0R / Ascorbic Acid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal and squamous cell carcinoma.

[MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Psoriasis / diagnosis. Skin Neoplasms / diagnosis

[MeSH-minor] Diagnosis, Differential. Eyelid Neoplasms / diagnosis. Humans

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Psoriasis.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17283757.001).

[ISSN] 0032-6518

[Journal-full-title] The Practitioner

[ISO-abbreviation] Practitioner

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 10

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of nonmelanoma skin cancer after human organ transplantation: single-center experience in Hungary.

There is increasing evidence that nonmelanoma skin cancers (NMSCs) are the most frequently observed tumors in transplant recipients.

All patients underwent a full skin examination for NMSC, and completed a standardized questionnaire.

Histologic analysis verified 13 basal cell carcinomas and 3 squamous cell carcinomas (ratio, 4:1).

These data indicate the relevance of skin cancer surveillance in transplant recipients.

Our results correspond to international statistics except for the ratio of basal cell carcinoma to squamous cell carcinoma.

[MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / epidemiology

[MeSH-minor] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Follow-Up Studies. Humans. Hungary / epidemiology. Kidney Transplantation / adverse effects. Male. Middle Aged. Pancreas Transplantation / adverse effects. Skin / pathology. Surveys and Questionnaires. Time Factors

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Organ Transplantation.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Inc. All rights reserved.

(PMID = 20692474.001).

[ISSN] 1873-2623

[Journal-full-title] Transplantation proceedings

[ISO-abbreviation] Transplant. Proc.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Atypical fibroxanthoma/malignant fibrous histiocytoma.

Atypical fibroxanthoma (AFX) is an unusual spindle cell tumor occurring on actinically damaged skin of the head and neck.

Clinically, it is often confused with basal cell carcinoma, squamous cell carcinoma, or even melanoma.

Although initially thought to be a diagnosis of exclusion histologically, newer immunostains have helped in the identification of AFX.

[MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Malignant Fibrous / pathology. Skin Neoplasms / pathology

[MeSH-minor] Humans. Mohs Surgery. Neoplasm Recurrence, Local

Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19076618.001).

[ISSN] 1529-8019

[Journal-full-title] Dermatologic therapy

[ISO-abbreviation] Dermatol Ther

[Language] eng

[Publication-type] Journal Article

[Publication-country] Denmark

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer].

[Transliterated title] Photochemische Internalisierung (PCI): eine Weiterentwicklung der photodynamischen Therapie zur Behandlung von Hautkrebs.

Recently, several new and non-invasive methods have been introduced for the treatment of skin cancers.

Topical creams using the immune modulator imiquimod or the COX inhibitor diclofenac (with hyaluronic acid) are now registered for use against neoplasms such as basal or squamous cell carcinoma.

A refined version of PDT, namely photochemical internalisation, is currently subject to a first clinical trial in patients with osteosarcoma, squamous cell carcinoma, head and neck cancer as well as adenocarcinoma of the breast.

[MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Melanoma / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

[MeSH-minor] Animals. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cytosol / drug effects. Endocytosis. Endosomes / drug effects. Humans. Melanoma, Experimental / drug therapy. Mice. Neoplasm Transplantation

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21082595.001).

[ISSN] 1661-8157

[Journal-full-title] Praxis

[ISO-abbreviation] Praxis (Bern 1994)

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ultraviolet radiation and malignant melanoma.

Essential features of the epidemiology and photobiology of cutaneous malignant melanoma (CMM) in Norway were studied in comparison with data from countries at lower latitudes.

This hypothesis was supported both by latitude gradients, by time trends and by changing patterns of tumor density on different body localizations.

Comparisons of skin cancer data from Norway and Australia/New Zealand indicate that squamous cell carcinoma and basal cell carcinoma are mainly related to annual solar UVB fluences, while UVA fluences play a larger role for CMM.

[MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18348451.001).

[ISSN] 0065-2598

[Journal-full-title] Advances in experimental medicine and biology

[ISO-abbreviation] Adv. Exp. Med. Biol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Number-of-references] 52

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Exposure to solar ultraviolet radiation (UV) is the main etiological factor for skin cancer, including melanoma.

Therefore, maintaining genomic stability of melanocytes is crucial for prevention of melanoma, as well as keratinocyte-derived basal and squamous cell carcinoma.

The response of melanocytes to UV is mediated mainly by a network of paracrine factors that not only activate melanogenesis, but also DNA repair, anti-oxidant, and survival pathways that are pivotal for maintenance of genomic stability and prevention of malignant transformation or apoptosis.

Unraveling these mechanisms might lead to strategies to prevent melanoma, as well as non-melanoma skin cancer.

[MeSH-major] DNA Repair / physiology. Genomic Instability. Melanocytes / metabolism. Melanoma / metabolism. Skin Neoplasms / metabolism. Ultraviolet Rays

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Pigment Cell Melanoma Res. 2011 Apr;24(2):265-7 [21513010.001]

(PMID = 20128873.001).

[ISSN] 1755-148X

[Journal-full-title] Pigment cell & melanoma research

[ISO-abbreviation] Pigment Cell Melanoma Res

[Language] eng

[Grant] United States / NIEHS NIH HHS / ES / P30-ES006096; United States / NCI NIH HHS / CA / R01CA114095; United States / NIEHS NIH HHS / ES / R01ES009110; United States / NIEHS NIH HHS / ES / R01ES017561

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review

[Publication-country] England

[Number-of-references] 197

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epidemiology of skin cancer: role of some environmental factors.

The incidence rate of melanoma and non-melanoma skin cancer entities is dramatically increasing worldwide.

Exposure to UVB radiation is known to induce basal and squamous cell skin cancer in a dose-dependent way and the depletion of stratospheric ozone has implications for increases in biologically damaging solar UVB radiation reaching the earth's surface.

In humans, arsenic is known to cause cancer of the skin, as well as cancer of the lung, bladder, liver, and kidney.

SCC and BCC (squamous and basal cell carcinoma) have been reported to be associated with ingestion of arsenic alone or in combination with other risk factors.

Higher temperatures accompanying climate change may lead, among many other effects, to increasing incidence of skin cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 24281212.001).

[ISSN] 2072-6694

[Journal-full-title] Cancers

[ISO-abbreviation] Cancers (Basel)

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

[Other-IDs] NLM/ PMC3840456

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies.

BACKGROUND: Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in the light-skinned population.

OBJECTIVE: The scope of this review is to present data on the current state-of-the-art diagnostic methods for keratinocyte carcinoma: basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.

[MeSH-major] Skin Neoplasms / diagnosis

[MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / ultrasonography. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Dermoscopy. Diagnostic Tests, Routine. Humans. Keratosis / diagnosis. Keratosis / pathology. Keratosis / ultrasonography

MedlinePlus Health Information. consumer health - Skin Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17903149.001).

[ISSN] 1076-0512

[Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

[ISO-abbreviation] Dermatol Surg

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 128

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.

[MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Disease Models, Animal. Estrogens / pharmacology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Skin Cancer.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] Carcinogenesis. 2009 Apr;30(4):720 [19168587.001]

(PMID = 19168582.001).

[ISSN] 1460-2180

[Journal-full-title] Carcinogenesis

[ISO-abbreviation] Carcinogenesis

[Language] eng

[Publication-type] Comment; Letter

[Publication-country] England

[Chemical-registry-number] 0 / Estrogens

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Skin cancer in organ transplant patients. Epidemiology and management].

Skin cancer is the most common cancer, representing 40-50% of post transplant malignancies.

In the first 10 years post transplantation, some 15%-40% of patients develop skin cancer, primarily squamous cell carcinoma and basal cell carcinoma, but also melanoma, Merkel cell carcinoma and virally-induced Kaposi sarcoma.

The management of skin cancer includes secondary prophylaxis and address attention to areas of widespread actinic damage, usually with topical agents.

In high risk skin cancer or metastatic disease a substantial reduction in immunosuppression to switching to mTOR inhibitors appears to substantially improve the prognosis.

The management of the individual tumor types is discussed; in general it follows the current guidelines.

[MeSH-major] Antineoplastic Agents / administration & dosage. Immunosuppressive Agents / administration & dosage. Organ Transplantation / statistics & numerical data. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Skin Neoplasms / epidemiology. Skin Neoplasms / prevention & control

MedlinePlus Health Information. consumer health - After Surgery.

MedlinePlus Health Information. consumer health - Organ Transplantation.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Melanoma Res. 2008 Apr;18(2):152-60 [18337653.001]

[Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S15-6 [18801136.001]

[Cites] Am J Transplant. 2008 Sep;8(9):1891-900 [18786232.001]

[Cites] Curr Opin Oncol. 2009 May;21(3):232-7 [19370807.001]

[Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]

[Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]

[Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]

[Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S2-4 [18801139.001]

[Cites] ScientificWorldJournal. 2008 Sep 21;8:909-19 [18836658.001]

[Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]

[Cites] J Am Acad Dermatol. 2005 Nov;53(5):783-90 [16243126.001]

[Cites] Am J Transplant. 2006 Sep;6(9):2164-8 [16780549.001]

[Cites] Transplantation. 2009 Aug 27;88(4):597-8 [19696647.001]

[Cites] Cancer. 2007 Jul 1;110(1):1-12 [17520670.001]

[Cites] Dermatol Surg. 2009 Oct;35(10):1567-72 [19681993.001]

[Cites] Am J Transplant. 2008 Nov;8(11):2192-8 [18782290.001]

[Cites] Dermatol Surg. 2002 Feb;28(2):113-7; discussion 117 [11860419.001]

[Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]

[Cites] Transplantation. 2006 Dec 27;82(12):1792-3 [17198278.001]

[Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]

[Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]

[Cites] Am J Transplant. 2004 Jun;4(6):905-13 [15147424.001]

[Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S19-24 [18801138.001]

[Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S9-S14 [18801142.001]

[Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8 [18801141.001]

[Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]

[Cites] Nat Clin Pract Oncol. 2008 Sep;5(9):510-1 [18679393.001]

[Cites] J Am Acad Dermatol. 2008 Sep;59(3):405-17 [18556089.001]

[Cites] Transplant Proc. 1988 Jun;20(3 Suppl 3):885-92 [3388524.001]

[Cites] Melanoma Res. 2008 Feb;18(1):61-7 [18227710.001]

[Cites] Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15 [19680830.001]

[Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]

[Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]

[Cites] Transplantation. 1997 Sep 15;64(5):669-73 [9311700.001]

[Cites] J Clin Microbiol. 2001 Feb;39(2):506-8 [11158097.001]

[Cites] Br J Dermatol. 2006 Aug;155(2):451-4 [16882188.001]

[Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]

[Cites] Transplantation. 2004 Feb 27;77(4):574-9 [15084938.001]

[Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]

[Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7 [15061846.001]

[Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]

[Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]

[Cites] Clin Oncol (R Coll Radiol). 2007 Jun;19(5):365-6 [17379490.001]

[Cites] Br J Dermatol. 2007 Dec;157(6):1183-8 [17916206.001]

[Cites] Arch Dermatol. 2001 Apr;137(4):459-63 [11295926.001]

(PMID = 20145902.001).

[ISSN] 1432-1173

[Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete

[ISO-abbreviation] Hautarzt

[Language] ger

[Publication-type] English Abstract; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Tumor types were squamous cell carcinoma, basal cell carcinoma, conjunctival squamous cell carcinoma, retinoblastoma, fibrosarcoma, and ectopic mixed tumor in two, one, two, one, one, and one patients, respectively, in addition to eight patients with jaw lymphoma involving the orbit, out of 24 patients reported by us.

Surgery consisted of complete excision of orbital content (exenteration) with or without partial orbitectomy in four patients and wide excision of the tumor in four patients.

Reconstruction of the defect was accomplished using various local skin flaps and temporalis muscle flap was used for augmenting the orbit in the four exenterated patients.

There is no single best method for reconstruction of the periorbital and orbital defects left after tumor resection, and different flaps applied for reconstruction had given satisfactory results related to the type and complexity of the deformity.

[MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Eye Enucleation. Female. Humans. Infant. Iraq. Lymphoma / chemistry. Lymphoma / surgery. Male. Middle Aged. Radiotherapy, Adjuvant. Skin Transplantation

MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17993883.001).

[ISSN] 1049-2275

[Journal-full-title] The Journal of craniofacial surgery

[ISO-abbreviation] J Craniofac Surg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Facial mutilant basosquamous carcinoma].

[Transliterated title] Carcinoma basoescamoso mutilante en región facial.

Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.

This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.

The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.

[MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods

[MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Palliative Care.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18293774.001).

[ISSN] 0303-8874

[Journal-full-title] Anales otorrinolaringológicos ibero-americanos

[ISO-abbreviation] An Otorrinolaringol Ibero Am

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

[Chemical-registry-number] 0 / Anti-Bacterial Agents

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Double skin tumors with an atypical clinical picture.

The authors present a rare case of double skin tumors: acral lentiginous melanoma and metatypical carcinoma.

The skin biopsies showed advanced acral lentiginous melanoma on the sole and metatypical carcinoma of the lower leg.

Soon after the diagnosis was made, the melanoma generalized.

The article discusses the differential diagnosis of both leg ulcerations, correct diagnostic procedures, and characteristic features of both tumors that are important questions for general practitioners, dermatologists, and surgeons.

[MeSH-major] Carcinoma / diagnosis. Leg Ulcer / etiology. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis

[MeSH-minor] Aged. Diagnosis, Differential. Foot Ulcer / etiology. Humans. Male

MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17992460.001).

[ISSN] 1318-4458

[Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica

[ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Slovenia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Early diagnosis of skin cancer].

The skin is the most affected organ by cancer.

The incidence rates of skin cancer are steadily increasing, both for melanoma and non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma).

Over 90 % of the death cases from skin cancers attribute to melanoma.

In the last years a number of new non invasive techniques for the early diagnosis of melanoma have been developed which are superior to the naked eye examination.

In this overview article we present some non-invasive diagnostic techniques like total body photography, digital dermoscopy and confocal microscopy which in addition to dermoscopy assist the dermatologist in differentiating nevi from early melanomas.Non-melanoma skin cancer can be prevented by accurate sun protection.

Early squamous cell carcinomas and basal cell carcinomas can be treated either invasively or non-invasively with excellent prognosis.

[MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / prevention & control. Melanoma / diagnosis. Melanoma / prevention & control. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control

[MeSH-minor] Dermoscopy. Early Diagnosis. Humans. Microscopy, Confocal. Photography. Risk Factors. Skin / pathology

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20806172.001).

[ISSN] 0040-5930

[Journal-full-title] Therapeutische Umschau. Revue thérapeutique

[ISO-abbreviation] Ther Umsch

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Switzerland

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Education in skin cancer management--assessing knowledge and safety.

BACKGROUND: General practitioners manage the majority of skin cancers in Australia.

There are a range of training opportunities for, and certifications in, skin cancer management.

METHOD: Between 15 June and 25 June 2008, an online examination was placed on the Australasian College of Skin Cancer Medicine website.

Thirty questions were asked pertaining to the management of a hypothetical case study including melanoma, basal cell carcinoma and squamous cell carcinoma.

Two days of training may not make doctors sufficiently safe in skin cancer management; it appeared to improved knowledge, but not to a point where unsafe practice was eliminated.

[MeSH-major] Family Practice / education. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19575076.001).

[ISSN] 0300-8495

[Journal-full-title] Australian family physician

[ISO-abbreviation] Aust Fam Physician

[Language] eng

[Publication-type] Journal Article

[Publication-country] Australia

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Microcystic adnexal carcinoma: an immunohistochemical reappraisal.

Even though immunohistochemical comparisons of microcystic adnexal carcinoma vs infiltrative basal cell carcinoma and desmoplastic trichoepithelioma exist, they are mostly restricted to the use of a single stain.

In addition, a comparison with squamous cell carcinoma has not been reported previously.

In this study, we compare the expression of cytokeratin (CK) 15, CK7, CK20, CK903, carcinoembryonic antigen (CEA), CD10, CD15 and BerEP4 in 13 microcystic adnexal carcinoma, eight desmoplastic trichoepithelioma, 10 infiltrative basal cell carcinoma, and eight squamous cell carcinoma of which five exhibited ductal differentiation.

We found that the majority of microcystic adnexal carcinoma (92%) and desmoplastic trichoepithelioma (100%) cases expressed CK15 while the infiltrative basal cell carcinoma and squamous cell carcinoma cases were all negative.

Forty percent of infiltrative basal cell carcinoma expressed CK7; while only two microcystic adnexal carcinoma cases (15%) and one squamous cell carcinoma with ductal differentiation (12%) expressed CK7 in the remaining three tumor categories.

While the neoplastic cells were negative, luminal staining of ductal structures was noted for CK7, CD15 and CEA in some of the microcystic adnexal carcinoma, desmoplastic trichoepithelioma and squamous cell carcinoma with ductal differentiation cases.

Sixty percent of infiltrative basal cell carcinoma, 31% of microcystic adnexal carcinoma, and 25% of squamous cell carcinoma express CD10.

BerEP4 expression was noted in 38% of microcystic adnexal carcinoma, 57% of desmoplastic trichoepithelioma, 100% of infiltrative basal cell carcinoma, and 38% of squamous cell carcinoma.

In conclusion, we found CK15 to be a useful marker in distinguishing microcystic adnexal carcinoma from infiltrative basal cell carcinoma and squamous cell carcinoma with ductal differentiation.

Our experience indicates that microcystic adnexal carcinoma and desmoplastic trichoepithelioma have a similar immunohistochemical profile that is, CK15+ and BerEP4+/-; thus, additional studies are needed to separate these two entities.

[MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Skin Appendage / chemistry. Head and Neck Neoplasms / chemistry. Immunohistochemistry / methods. Skin Neoplasms / chemistry

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Humans. Keratin-15 / analysis. Male. Middle Aged

Genetic Alliance. consumer health - Microcystic adnexal carcinoma.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18065959.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-15; 0 / human epithelial antigen-125

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Giant meta-typical carcinoma: an unusual tumor.

Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.

It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.

Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.

Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.

This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.

This central tumor regression is to our knowledge a unique finding in MTC.

[MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16603102.001).

[ISSN] 1330-027X

[Journal-full-title] Acta dermatovenerologica Croatica : ADC

[ISO-abbreviation] Acta Dermatovenerol Croat

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Croatia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [UV-induced skin cancers].

In this review the epidemiology and pathogenetic aspects of UV-induced malignant skin tumours (basal cell carcinoma, squamous cell carcinoma and melanoma) are discussed with regard to current literature.

Whereas present knowledge, in particular, gained from experimental data, permits substantial conclusions about the development of squamous cell carcinoma, the situation for basal cell carcinoma and melanoma does not appear to be unequivocally clear.

[MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Melanoma / etiology. Neoplasms, Radiation-Induced / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects

[MeSH-minor] Adolescent. Age Factors. Child. DNA Damage. DNA Repair. Humans. Risk Factors. Skin / pathology. Sunburn / complications

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16117740.001).

[ISSN] 1610-0379

[Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

[ISO-abbreviation] J Dtsch Dermatol Ges

[Language] ger

[Publication-type] Comparative Study; English Abstract; Journal Article; Review

[Publication-country] Germany

[Number-of-references] 37

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus).

Six additional variably sized, raised, smooth to cauliflower-like skin masses were observed randomly distributed throughout the left wing membranes.

Four masses were removed and diagnosed microscopically as basosquamous carcinomas and papillomas.

Additional masses, removed 6 mo and 1 yr later, showed bony invasion and squamous differentiation.

Polymerase chain reaction done on DNA extracts from formalin-fixed, paraffin-embedded tumor tissue amplified a 450 base-pair segment analogous to the L1 region of human papillomavirus types 96 and 5.

To our knowledge, this is the first report of papillomavirus-associated carcinoma in a chiropteran species.

[MeSH-major] Carcinoma, Squamous Cell / veterinary. Chiroptera / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Skin Neoplasms / veterinary

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17312801.001).

[ISSN] 1042-7260

[Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians

[ISO-abbreviation] J. Zoo Wildl. Med.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metatypical basal cell carcinoma: a clinical review.

BACKGROUND: Metatypical cell carcinoma can be considered as a new entity of skin cancer, being an intermediate typology between basal cell carcinomas and squamous cell carcinomas.

The behaviour of the metatypical cell carcinoma lies between these two varieties of skin cancer.

It is difficult to perform a differential diagnosis based on morphological and clinical features - therefore it is only possible by accurate histology.

METHODS: The authors have retrospectively analysed clinical records of 240 patients who were affected by metatypical skin cancer and who were treated by surgery, radiotherapy and chemotherapy.

CONCLUSION: In this manuscript, the authors have emphasised the importance of conducting a differential diagnosis, and the importance of the specific treatment for metatypical skin cancer, even though more clinical studies and long-term follow-ups are required before establishing specific guidelines.

[MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Skin Cancer.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]

[Cites] Plast Reconstr Surg. 2001 Apr 1;107(4):942-7 [11252086.001]

[Cites] Plast Reconstr Surg. 2002 Apr 1;109(4):1466-7 [11965016.001]

[Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]

[Cites] Virchows Arch. 2002 Dec;441(6):551-8 [12461611.001]

[Cites] Otolaryngol Head Neck Surg. 2003 May;128(5):663-73 [12748559.001]

[Cites] Dermatol Surg. 2003 Jul;29(7):700-11 [12828693.001]

[Cites] Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833 [12859383.001]

[Cites] J Craniomaxillofac Surg. 2004 Feb;32(1):16-8 [14729044.001]

[Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):248-52 [14871217.001]

[Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]

[Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]

[Cites] Arch Facial Plast Surg. 2004 May-Jun;6(3):158-61 [15148122.001]

[Cites] Br J Oral Maxillofac Surg. 2004 Aug;42(4):311-4 [15225948.001]

[Cites] Arch Dermatol. 1965 Dec;92(6):635-7 [5846318.001]

[Cites] Br J Dermatol. 1973 Jul;89(1):37-43 [4788317.001]

[Cites] Ophthalmologica. 1983;187(1):51-8 [6877760.001]

[Cites] Arkh Patol. 1983;45(6):35-9 [6625927.001]

[Cites] J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):557-62 [6490979.001]

[Cites] Dermatologica. 1985;171(1):21-6 [2411609.001]

[Cites] Arch Dermatol. 1987 Mar;123(3):340-4 [3813602.001]

[Cites] J Dermatol Surg Oncol. 1987 May;13(5):556-7 [3571694.001]

[Cites] J Dermatol Surg Oncol. 1988 Jun;14(6):600-2 [3372843.001]

[Cites] Dermatol Clin. 1988 Jul;6(3):397-405 [3048822.001]

[Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]

[Cites] J Am Acad Dermatol. 1992 Jan;26(1):1-26 [1732313.001]

[Cites] Pathol Res Pract. 1991 Dec;187(8):978-85 [1792194.001]

[Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]

[Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]

[Cites] J Invest Dermatol. 1994 Jun;102(6):6S-9S [8006441.001]

[Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]

[Cites] Arkh Patol. 1994 Jul-Aug;56(4):35-8 [7848103.001]

[Cites] Ann Chir Plast Esthet. 1994 Apr;39(2):176-83 [7872634.001]

[Cites] Am J Surg. 1995 Nov;170(5):446-50 [7485729.001]

[Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]

[Cites] Am J Dermatopathol. 1996 Feb;18(1):35-42 [8721589.001]

[Cites] Neurosurgery. 1997 Jul;41(1):279-81; discussion 281-2 [9218319.001]

[Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7 [9308559.001]

[Cites] Clin Plast Surg. 1997 Oct;24(4):627-36 [9342506.001]

[Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]

[Cites] J Cutan Pathol. 1998 Mar;25(3):153-9 [9550314.001]

[Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]

[Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]

[Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]

[Cites] Cancer. 2005 Jul 1;104(1):170-5 [15929123.001]

[Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]

[Cites] J Am Acad Dermatol. 2005 Sep;53(3):464-8 [16112354.001]

[Cites] J Plast Reconstr Aesthet Surg. 2007;60(1):41-7 [17126265.001]

[Cites] Eur J Dermatol. 2000 Jun;10(4):315-6 [10939863.001]

[Cites] Br J Oral Maxillofac Surg. 2000 Oct;38(5):477-9 [11010777.001]

[Cites] J Natl Compr Canc Netw. 2004 Jan;2(1):2 [19777690.001]

(PMID = 18992138.001).

[ISSN] 1756-9966

[Journal-full-title] Journal of experimental & clinical cancer research : CR

[ISO-abbreviation] J. Exp. Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Italy

[Number-of-references] 55

[Other-IDs] NLM/ PMC2585560